Tokyo, Jan 14, 2010 (JCN Newswire) - Eisai Co., Ltd. announced today that the Company has submitted an application for approval of an additional indication of anti-arrhythmic agent Tambocor(R) 50mg Tablets and Tambocor(R) 100mg Tablets (generic name: flecainide acetate) for the treatment of tachyarrhythmia (paroxysmal atrial fibrillation/flutter, paroxysmal supraventricular tachycardia, ventricular tachycardia) in paediatric patients in Japan.
